Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05186462 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Intravenous: PF-05186462 | ACTIVE_COMPARATOR | - |
| Oral: PF-05186462 | ACTIVE_COMPARATOR | - |
| Intravenous: PF-05089771 | ACTIVE_COMPARATOR | - |
| Oral: PF-05089771 | ACTIVE_COMPARATOR | - |
| Intravenous: PF-05150122 | ACTIVE_COMPARATOR | - |
| Oral: PF-05150122 | ACTIVE_COMPARATOR | - |
| Intravenous: PF-05241328 | ACTIVE_COMPARATOR | - |
| Oral: PF-05241328 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-05186462 | DRUG | single intravenous infusion of 100 microgram |
| PF-05089771 | DRUG | single intravenous infusion of 100 microgram of PF-05089771 |
| PF-05150122 | DRUG | single intravenous administration of 100 microgram PF-05150122 |
| PF-05241328 | DRUG | single intravenous infusion of 100 microgram PF-05241328 |
Inclusion Criteria: * healthy male subjects between the ages of 18 and 50 years inclusive. (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12-lead ECG and clinical la...
PF-05186462 is an investigational small molecule being developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The compound has been studied in healthy volunteers to assess its pharmacokinetics, which is how the drug is absorbed, distributed, metabolized, and excreted by the body.
PF-05186462 is being studied in healthy volunteers as part of early clinical research. The completed Phase 1 trial was designed to evaluate the pharmacokinetics of the compound following a very low dose. Its intended therapeutic use has not been established, as it is still in early-stage development.
PF-05186462 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this investigational small molecule in healthy volunteers.
PF-05186462 is in Phase 1 clinical development. One Phase 1 trial has been completed, which enrolled 40 healthy male participants in the United Kingdom. The study was active-controlled and focused on measuring the pharmacokinetics of the compound at a very low dose.
PF-05186462 has one completed clinical trial registered as NCT01165736. This Phase 1 study enrolled 40 healthy male volunteers aged 18 years and older in the United Kingdom. The trial was designed to calculate the pharmacokinetics of the compound following a very low dose that would not have pharmacological activity.
PF-05186462 is an investigational compound with no alternative names listed in its clinical trial registration. It is being studied under this identifier by Pfizer, Inc. in early-stage research involving healthy volunteers.